Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel large and small molecule therapeutic candidates, enabling faster medicines to patients. Carterra’s high throughput screening and characterization technology combines patented microfluidics with real-time High Throughput Surface Plasmon Resonance (HT-SPR) instruments, consumables, and industry-leading Kinetic and Epitope Analysis and Visualization Software™, delivering up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing platforms. Carterra technology condenses months of work into a few days.
Read about Carterra in the news:
- Carterra unveils its most sensitive biosensor platform; Carterra Ultra™ ushers in a new frontier in fragment and small molecule drug discovery
- Standard BioTools Purchases the Carterra® LSAXT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan® Customers
- IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
- Ordaōs Acquires the Carterra®LSA® Platform to Further Speed and Optimize Its Machine-Driven Drug Design System
- ENPICOM and Carterra Advance Antibody Screening by Integrating Biophysical Characterization and Repertoire Sequencing Analysis
- Icosagen Acquires the Carterra LSA Instrument to Significantly Enhance Its Antibody Screening Capabilities in the Discovery and Development of New Therapeutic and Diagnostic Antibodies
- Carterra expands best-in-class franchise with the launch of the LSAXT high-throughput SPR biosensor at SLAS 2023
- More News